Published in Proc Natl Acad Sci U S A on March 05, 2007
TGFbeta in Cancer. Cell (2008) 17.44
Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome. Immunity (2009) 2.84
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol (2010) 2.61
The TGF-beta paradox in human cancer: an update. Future Oncol (2009) 1.79
Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem (2009) 1.67
TGF-beta1 induced epithelial to mesenchymal transition (EMT) in human bronchial epithelial cells is enhanced by IL-1beta but not abrogated by corticosteroids. Respir Res (2009) 1.32
Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res (2008) 1.31
Epithelial-to-mesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-kappaB/Snail1 pathway. Dis Model Mech (2008) 1.18
Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol (2014) 1.17
NF-κB and cancer: a paradigm of Yin-Yang. Am J Cancer Res (2010) 1.08
Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. J Biol Chem (2008) 1.08
Interleukins in glioblastoma pathophysiology: implications for therapy. Br J Pharmacol (2013) 1.07
Interleukin 1 alpha (IL1A) is a novel regulator of the blood-testis barrier in the rat. Biol Reprod (2007) 1.02
The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. Carcinogenesis (2009) 1.02
Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. Cancer Res (2010) 0.96
Occlusion regulates epidermal cytokine production and inhibits scar formation. Wound Repair Regen (2010) 0.94
Critical role of NF-κB in pancreatic cancer. Oncotarget (2014) 0.93
Use of forward genetics to discover novel regulators of NF-kappaB. Cold Spring Harb Perspect Biol (2009) 0.93
Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. J Bone Miner Res (2010) 0.92
Interleukin-1β and transforming growth factor-β cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells. Stem Cell Res Ther (2012) 0.92
Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness. Mol Cancer Res (2008) 0.91
Aberrant expression of interleukin-1β and inflammasome activation in human malignant gliomas. PLoS One (2014) 0.90
NFkappaB mediates IL-1beta-induced down-regulation of TbetaRII through the modulation of Sp3 expression. J Cell Mol Med (2007) 0.90
Inhibition of transforming growth factor-activated kinase 1 (TAK1) blocks and reverses epithelial to mesenchymal transition of mesothelial cells. PLoS One (2012) 0.90
Roles of tumor suppressors in regulating tumor-associated inflammation. Cell Death Differ (2014) 0.89
Inhibition of proinflammatory RANTES expression by TGF-beta1 is mediated by glycogen synthase kinase-3beta-dependent beta-catenin signaling. J Biol Chem (2010) 0.88
Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells. Proc Natl Acad Sci U S A (2008) 0.85
IL-1β promotes TGF-β1 and IL-2 dependent Foxp3 expression in regulatory T cells. PLoS One (2011) 0.84
Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor β activity in carcinomas. Semin Radiat Oncol (2013) 0.83
Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis. Cancer Prev Res (Phila) (2010) 0.83
Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression. J Proteomics (2014) 0.81
Caspase-1 inhibitors from an extremophilic fungus that target specific leukemia cell lines. J Nat Prod (2012) 0.80
Activation of cAMP-responsive-element-binding protein by PI3 kinase and p38 MAPK is essential for elevated expression of transforming growth factor β2 in cancer cells. J Interferon Cytokine Res (2010) 0.76
NF-kappaB at the crossroads of life and death. Nat Immunol (2002) 12.98
Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol (2003) 7.74
Inferences, questions and possibilities in Toll-like receptor signalling. Nature (2004) 7.57
TRAF6 is a signal transducer for interleukin-1. Nature (1996) 7.38
Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science (1995) 6.81
Signal transduction by the TGF-beta superfamily. Science (2002) 5.61
TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev (2002) 4.66
TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J (2002) 3.80
The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev (2002) 3.69
Mutant cells that do not respond to interleukin-1 (IL-1) reveal a novel role for IL-1 receptor-associated kinase. Mol Cell Biol (1999) 2.77
Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science (2000) 2.67
Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol Cell Biol (2002) 2.47
NFkappaB-dependent signaling pathways. Exp Hematol (2002) 1.98
BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem (2000) 1.93
The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res (2006) 1.68
Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc Natl Acad Sci U S A (1997) 1.67
Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci U S A (2004) 1.45
Smad6 negatively regulates interleukin 1-receptor-Toll-like receptor signaling through direct interaction with the adaptor Pellino-1. Nat Immunol (2006) 1.42
Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. Am J Pathol (2004) 1.39
Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer. Oncogene (2004) 1.38
Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells (2001) 1.38
Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle (2004) 1.34
The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. J Biol Chem (2006) 1.33
IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness. J Biol Chem (2004) 1.23
TGF-{beta}1 activates two distinct type I receptors in neurons: implications for neuronal NF-{kappa}B signaling. J Cell Biol (2005) 1.19
Activations of ERK1/2 and JNK by transforming growth factor beta negatively regulate Smad3-induced alkaline phosphatase activity and mineralization in mouse osteoblastic cells. J Biol Chem (2002) 1.16
Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression. BMC Cell Biol (2006) 1.02
A role for Stat1 in the regulation of lipopolysaccharide-induced interleukin-1beta expression. J Interferon Cytokine Res (2006) 1.00
Persistent interleukin-1beta signaling causes long term activation of NFkappaB in a promoter-specific manner in human glial cells. J Biol Chem (2006) 0.93
Effects of TGF-beta, TNF-alpha, IL-beta and IL-6 alone or in combination, and tyrosine kinase inhibitor on cyclooxygenase expression, prostaglandin E2 production and bone resorption in mouse calvarial bone cells. Int J Biochem Cell Biol (2004) 0.91
Inhibition of the transforming growth factor beta (TGFbeta) pathway by interleukin-1beta is mediated through TGFbeta-activated kinase 1 phosphorylation of SMAD3. Mol Biol Cell (2005) 0.90
A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. Cancer Lett (2006) 0.87
Autoregulation of the interleukin-1 system and cytokine-cytokine interactions in primary human astrocytoma cells. Brain Res Bull (2000) 0.86
TGF-beta down-regulates IL-1alpha-induced TLR2 expression in murine hepatocytes. J Leukoc Biol (2004) 0.84
Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells. Eur J Endocrinol (2005) 0.81
Enhanced interleukin-1 beta release and longevity of glioma-associated peripheral blood monocytes in vitro. Neurosurgery (1994) 0.80
Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov (2007) 6.33
Complex modulation of cell type-specific signaling in response to type I interferons. Immunity (2006) 4.48
SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol (2003) 3.69
Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol (2002) 3.64
Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev (2007) 3.57
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res (2005) 3.10
Roles of unphosphorylated STATs in signaling. Cell Res (2008) 2.27
Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem (2001) 2.21
IRF-3-dependent, NFkappa B- and JNK-independent activation of the 561 and IFN-beta genes in response to double-stranded RNA. Proc Natl Acad Sci U S A (2002) 2.20
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A (2005) 2.14
Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A (2009) 2.10
Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci U S A (2010) 2.06
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res (2006) 2.03
NFkappaB-dependent signaling pathways. Exp Hematol (2002) 1.98
Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem (2004) 1.88
The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci U S A (2003) 1.80
Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A (2009) 1.78
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol (2010) 1.78
The Sm-protein methyltransferase, dart5, is essential for germ-cell specification and maintenance. Curr Biol (2006) 1.78
Two distinct arginine methyltransferases are required for biogenesis of Sm-class ribonucleoproteins. J Cell Biol (2007) 1.58
Transposon-based mutagenesis identifies short RIP1 as an activator of NFkappaB. Cell Cycle (2008) 1.49
Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc Natl Acad Sci U S A (2009) 1.49
The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res (2010) 1.48
Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci U S A (2004) 1.45
Interleukin-1 receptor-associated kinase 2 is critical for lipopolysaccharide-mediated post-transcriptional control. J Biol Chem (2009) 1.42
p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2. J Cell Sci (2005) 1.39
Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer. Oncogene (2004) 1.38
Identification of a human NF-kappaB-activating protein, TAB3. Proc Natl Acad Sci U S A (2004) 1.37
Reduced viability, fertility and fecundity in mice lacking the cajal body marker protein, coilin. PLoS One (2009) 1.35
Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle (2004) 1.34
G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res (2003) 1.31
Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res (2009) 1.31
Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption. J Neurosci (2003) 1.27
IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J (2013) 1.26
Major differences in the responses of primary human leukocyte subsets to IFN-beta. J Immunol (2010) 1.26
Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. J Neurooncol (2007) 1.22
PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB. Proc Natl Acad Sci U S A (2013) 1.17
Down-regulation of p53 by double-stranded RNA modulates the antiviral response. J Virol (2005) 1.17
Mutagenesis by reversible promoter insertion to study the activation of NF-kappaB. Proc Natl Acad Sci U S A (2005) 1.17
Mutant human cells with constitutive activation of NF-kappaB. Proc Natl Acad Sci U S A (2003) 1.14
Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors. Proc Natl Acad Sci U S A (2006) 1.11
Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc Natl Acad Sci U S A (2013) 1.11
DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation. Proc Natl Acad Sci U S A (2008) 1.10
STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc Natl Acad Sci U S A (2013) 1.10
Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development. Circulation (2007) 1.09
Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res (2005) 1.09
Limited role of N-terminal phosphoserine residues in the activation of transcription by p53. Oncogene (2004) 1.09
Pertussis toxin-induced reversible encephalopathy dependent on monocyte chemoattractant protein-1 overexpression in mice. J Neurosci (2002) 1.08
Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells. J Biol Chem (2006) 1.08
p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21. Cancer Res (2007) 1.07
A 32 kb critical region excluding Y402H in CFH mediates risk for age-related macular degeneration. PLoS One (2011) 1.05
Inhibitor of kappaB kinase is required to activate a subset of interferon gamma-stimulated genes. Proc Natl Acad Sci U S A (2004) 1.04
Role of tyrosine 441 of interferon-gamma receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation. J Biol Chem (2004) 1.04
Stat1-dependent, p53-independent expression of p21(waf1) modulates oxysterol-induced apoptosis. Mol Cell Biol (2002) 1.03
PHF20 regulates NF-κB signalling by disrupting recruitment of PP2A to p65. Nat Commun (2013) 1.02
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol (2012) 1.01
FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J Clin Invest (2012) 1.00
Stat3 activation is required for the growth of U87 cell-derived tumours in mice. Eur J Cancer (2008) 0.97
Sm protein methylation is dispensable for snRNP assembly in Drosophila melanogaster. RNA (2008) 0.97
Roles of IKK-beta, IRF1, and p65 in the activation of chemokine genes by interferon-gamma. J Interferon Cytokine Res (2009) 0.95
Use of forward genetics to discover novel regulators of NF-kappaB. Cold Spring Harb Perspect Biol (2009) 0.93
Requirement of phosphoinositide 3-kinase and Akt for interferon-beta-mediated induction of the beta-R1 (SCYB11) gene. J Biol Chem (2002) 0.93
TNF-alpha microinjection upregulates chemokines and chemokine receptors in the central nervous system without inducing leukocyte infiltration. J Interferon Cytokine Res (2003) 0.92
Role of lysine methylation of NF-κB in differential gene regulation. Proc Natl Acad Sci U S A (2013) 0.92
Engineering three-dimensional cell mechanical microenvironment with hydrogels. Biofabrication (2012) 0.90
Caspase-8-mediated cleavage inhibits IRF-3 protein by facilitating its proteasome-mediated degradation. J Biol Chem (2011) 0.89
Modification of hyaluronan by heavy chains of inter-α-inhibitor in idiopathic pulmonary arterial hypertension. J Biol Chem (2014) 0.89
Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas. Fertil Steril (2008) 0.88
FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB. Proc Natl Acad Sci U S A (2011) 0.88
Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1). J Interferon Cytokine Res (2002) 0.86
IRAK-dependent phosphorylation of Stat1 on serine 727 in response to interleukin-1 and effects on gene expression. J Interferon Cytokine Res (2003) 0.86
Regulation of the accumulation and function of p53 by phosphorylation of two residues within the domain that binds to Mdm2. J Biol Chem (2001) 0.86
The dual functions of IL-1 receptor-associated kinase 2 in TLR9-mediated IFN and proinflammatory cytokine production. J Immunol (2011) 0.86
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat (2011) 0.85
17β-Estradiol protects the liver against cold ischemia/reperfusion injury through the Akt kinase pathway. J Surg Res (2012) 0.84
The role of cell type-specific responses in IFN-β therapy of multiple sclerosis. Proc Natl Acad Sci U S A (2011) 0.84
Activation of a subset of genes by IFN-gamma requires IKKbeta but not interferon-dependent activation of NF-kappaB. J Interferon Cytokine Res (2007) 0.84
Interferon signaling is dependent on specific tyrosines located within the intracellular domain of IFNAR2c. Expression of IFNAR2c tyrosine mutants in U5A cells. J Biol Chem (2001) 0.83
Potential application of titanium dioxide nanoparticles in the prevention of osteosarcoma and chondrosarcoma recurrence. J Nanosci Nanotechnol (2013) 0.80
Using sequential immunoprecipitation and mass spectrometry to identify methylation of NF-κB. Methods Mol Biol (2015) 0.78
Calcifying pseudoneoplasm of the neuraxis overlying the corpus callosum: a case report and review of the literature. Clin Neuropathol (2013) 0.78
Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs. Int J Cancer (2014) 0.78
GNOSIS: guidelines for neuro-oncology: standards for investigational studies--reporting of surgically based therapeutic clinical trials. J Neurooncol (2006) 0.77
Pillars article: A protein tyrosine kinase in the interferon α/β signaling pathway. Cell. 1992. 70: 313-322. J Immunol (2011) 0.76
Activation of cAMP-responsive-element-binding protein by PI3 kinase and p38 MAPK is essential for elevated expression of transforming growth factor β2 in cancer cells. J Interferon Cytokine Res (2010) 0.76
Identification of interacting proteins for calcium-dependent protein kinase 8 by a novel screening system based on bimolecular fluorescence complementation. Biosci Biotechnol Biochem (2014) 0.76
Early diagnostic value of low percentage of glycosylated ferritin in secondary hemophagocytic lymphohistiocytosis. Int J Hematol (2009) 0.75